Artificial Intelligence in Genomics Market Size to Hit USD 14.37 Billion by 2033

Artificial Intelligence in Genomics Market Size, Share, Growth, Trends, Segmental Analysis, By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Generative AI, Other Technologies), By Application (Drug Discovery & Development, Precision Oncology, Rare Disease Diagnosis, Agricultural Genomics, Pharmacogenomics, Population Genomics, Other Applications), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Hospitals & Diagnostic Laboratories, Government & Public Health Organizations, Other End Users), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Mar, 2026
  • Report ID: 471
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Artificial Intelligence in Genomics Market Size to Hit USD 14.37 Billion by 2033

(An Updated Version is Available)

1. Executive Summary

  • 1.1 Market Overview and Definition

  • 1.2 Key Market Highlights and Findings

  • 1.3 Market Size and Growth Projections (2025–2033)

  • 1.4 Market Segmentation Snapshot

  • 1.5 Regional Market Snapshot

  • 1.6 Competitive Landscape Overview

  • 1.7 Key Growth Drivers and Strategic Insights

2. Research Methodology

  • 2.1 Research Framework and Approach

  • 2.2 Data Collection Methods

    • 2.2.1 Primary Research (Expert Interviews, Genomics Scientists, C‑Suite Consultation)

    • 2.2.2 Secondary Research (Industry Reports, Clinical Publications, Company Filings, Patent Databases)

  • 2.3 Market Size Estimation Methodology

    • 2.3.1 Top‑Down Approach

    • 2.3.2 Bottom‑Up Approach

  • 2.4 Data Triangulation and Validation Process

  • 2.5 Forecasting Models and Techniques

  • 2.6 Research Assumptions and Limitations

  • 2.7 Base Year (2025), Current Year (2026), and Forecast Period (2026–2033)

3. Market Introduction

  • 3.1 Market Definition and Scope

  • 3.2 Overview of Artificial Intelligence in Genomics

  • 3.3 Evolution of AI‑Driven Genomics: From Sanger Sequencing to NGS and AI‑Powered Analysis

  • 3.4 Market Taxonomy and Segmentation Framework

  • 3.5 Key Market Indicators and CAGR Highlights​

  • 3.6 Currency and Units Considered

  • 3.7 Stakeholder Ecosystem

4. AI in Genomics Market Characteristics

  • 4.1 Component Overview (Software, Services, Hardware)​

  • 4.2 AI Technology Types (Machine Learning, Deep Learning, Natural Language Processing, Other AI)

  • 4.3 Functionality Overview (Genome Sequencing, Gene Expression, Predictive Genomics, Population Genomics, Drug Discovery)

  • 4.4 Deployment Mode Comparison (Cloud‑Based vs. On‑Premise)

  • 4.5 Branded vs. Open‑Source AI Genomics Platforms

5. Assumptions and Acronyms Used

  • 5.1 List of Key Assumptions

  • 5.2 Currency and Pricing Considerations

  • 5.3 Acronyms and Abbreviations

6. Market Dynamics

  • 6.1 Introduction

  • 6.2 Market Drivers

    • 6.2.1 Rapid Growth in Volume of Genomic and Biomedical Data (NGS, WGS, Multi‑Omics)

    • 6.2.2 Rising Demand for Precision Medicine and Personalized Therapeutics

    • 6.2.3 Acceleration of Drug Discovery and Development Using AI Algorithms

    • 6.2.4 Advances in Machine Learning, Deep Learning, and NLP for Genomic Interpretation

    • 6.2.5 Growing Government Funding and Population‑Scale Genomics Programs

  • 6.3 Market Restraints

    • 6.3.1 Shortage of Skilled AI and Bioinformatics Workforce​

    • 6.3.2 Ambiguous Regulatory Guidelines for AI‑Based Genomics Software​

    • 6.3.3 Data Privacy, Security, and Storage Challenges with Large‑Scale Genomic Datasets

    • 6.3.4 High Cost of Next‑Generation Sequencing Platforms and AI Infrastructure

  • 6.4 Market Opportunities

    • 6.4.1 Expansion in Emerging Markets (Asia‑Pacific, Latin America)

    • 6.4.2 Integration of AI with Single‑Cell Genomics, Spatial Transcriptomics, and Multi‑Omics

    • 6.4.3 Development of AI‑Powered Companion Diagnostics and Pharmacogenomics

    • 6.4.4 National Biobank Initiatives and Population‑Scale Genomics Programs

  • 6.5 Market Challenges

    • 6.5.1 Ensuring Interpretability and Explainability of AI Models in Clinical Genomics

    • 6.5.2 Managing Interoperability Across Diverse Genomics Platforms and EHR Systems

    • 6.5.3 Balancing Innovation, Cost, and Regulatory Compliance​

    • 6.5.4 Ethical Concerns Around Genomic Data Ownership and Consent

  • 6.6 Market Trends

    • 6.6.1 Dominance of Machine Learning and Deep Learning in Genomic Data Analysis

    • 6.6.2 Rapid Adoption of Cloud‑Based AI Genomics Platforms

    • 6.6.3 Integration of AI with Single‑Cell Sequencing and Spatial Genomics​

    • 6.6.4 Growth of AI‑Driven Variant Calling, Gene Annotation, and Functional Impact Prediction​

    • 6.6.5 Emergence of Large Language Models (LLMs) and Generative AI for Genomics Research​

7. Value Chain and Ecosystem Analysis

  • 7.1 Overview of AI in Genomics Value Chain

  • 7.2 Data Generators (NGS Platforms, Biobanks, Clinical Sequencing Labs)

  • 7.3 AI Software and Algorithm Developers

  • 7.4 Cloud and HPC Infrastructure Providers

  • 7.5 Bioinformatics and Data Analytics Firms

  • 7.6 End Users (Pharma, Biotech, Healthcare Providers, Research Institutes)​

  • 7.7 Regulatory and Certification Bodies (FDA, EMA, NIH)

  • 7.8 Value Addition at Each Stage

8. Porter's Five Forces Analysis

  • 8.1 Threat of New Entrants

  • 8.2 Bargaining Power of Suppliers (NGS Platform and Cloud Providers)

  • 8.3 Bargaining Power of Buyers (Pharma, Biotech, Healthcare Providers)

  • 8.4 Threat of Substitute Technologies (Traditional Bioinformatics, Non‑AI Genomic Tools)

  • 8.5 Intensity of Competitive Rivalry

9. PESTEL Analysis

  • 9.1 Political Factors (Government Genomics Initiatives, Funding, Trade Regulations)

  • 9.2 Economic Factors (Healthcare & R&D Spending, NGS Cost Decline, Pharma Investment)​

  • 9.3 Social Factors (Precision Medicine Awareness, Patient Advocacy, Genetic Testing Adoption)​

  • 9.4 Technological Factors (Deep Learning, NLP, Cloud Computing, Edge AI, LLMs)

  • 9.5 Environmental Factors (Energy‑Efficient HPC, Sustainable Data Center Infrastructure)

  • 9.6 Legal and Regulatory Factors (HIPAA, GDPR, FDA SaMD Guidelines, Genomic Data Privacy Laws)​

10. Market Attractiveness Analysis

  • 10.1 By Component (Software, Services, Hardware)​

  • 10.2 By AI Technology (Machine Learning, Deep Learning, Natural Language Processing, Other AI)

  • 10.3 By Functionality (Genome Sequencing, Gene Expression, Predictive Genomics, Population Genomics, Drug Discovery & Others)

  • 10.4 By Application (Drug Discovery & Development, Diagnostics, Precision Medicine, Agriculture & Animal Genomics, Others)

  • 10.5 By Deployment Mode (Cloud‑Based, On‑Premise)

  • 10.6 By End User (Pharmaceutical & Biotech Companies, Hospitals & Healthcare Providers, Research Institutes & Academic Centers, Others)​

  • 10.7 By Region

11. COVID‑19 Impact Analysis

  • 11.1 Introduction and Overview

  • 11.2 Accelerated Adoption of AI Genomics in Pathogen Surveillance and Vaccine Development

  • 11.3 Supply Chain Disruptions in NGS Reagents and Sequencing Platforms

  • 11.4 Long‑Term Structural Impact: Telehealth, Remote Genomics, and Bioinformatics Cloud Adoption

  • 11.5 Post‑Pandemic Recovery and Market Normalization

12. Impact of Generative AI and Large Language Models on AI in Genomics Market

  • 12.1 Introduction to LLMs and Generative AI in Genomics Research​

  • 12.2 Applications in Gene Function Prediction, Protein Folding, and Variant Interpretation

  • 12.3 Integration with Multi‑Omics, Single‑Cell Sequencing, and Spatial Transcriptomics​

  • 12.4 Regulatory and Ethical Considerations for Generative AI in Clinical Genomics

  • 12.5 Future Technology‑Driven Market Opportunities

13. Global Artificial Intelligence in Genomics Market Size and Forecast (2025–2033)

  • 13.1 Historical Market Size and Trends (2021–2024)

  • 13.2 Base Year Market Size (2025)​

  • 13.3 Current Year Market Size (2026)​

  • 13.4 Market Size Forecast (USD Billion, 2026–2033)

  • 13.5 Year‑on‑Year Growth Analysis

  • 13.6 CAGR Analysis (2026–2033)​

  • 13.7 Absolute Dollar Opportunity Assessment

14. Market Segmentation Analysis

14.1 By Component​

  • 14.1.1 Software

    • AI‑Based Bioinformatics Software

    • Genomic Data Analysis Platforms

    • Clinical Decision Support Tools

  • 14.1.2 Services

    • Managed Services

    • Professional Services (Consulting, Integration, Training)

  • 14.1.3 Hardware

    • GPUs and AI Accelerators

    • HPC Servers and Sequencing Instruments

14.2 By AI Technology

  • 14.2.1 Machine Learning

    • Supervised Learning

    • Unsupervised Learning

    • Reinforcement Learning

  • 14.2.2 Deep Learning

    • Convolutional Neural Networks (CNNs)

    • Recurrent Neural Networks (RNNs)

    • Autoencoders

  • 14.2.3 Natural Language Processing (NLP)

    • Text Mining and Literature Extraction

    • Sentiment and Clinical Narrative Analysis

  • 14.2.4 Other AI Technologies (Generative AI, LLMs, Federated Learning)

14.3 By Functionality

  • 14.3.1 Genome Sequencing

  • 14.3.2 Gene Expression Analysis

  • 14.3.3 Predictive Genomics and Genetic Risk Prediction

  • 14.3.4 Population Genomics

  • 14.3.5 Drug Discovery and Target Identification

  • 14.3.6 Others (Epigenomics, Pharmacogenomics, Structural Genomics)

14.4 By Application

  • 14.4.1 Drug Discovery and Development

  • 14.4.2 Diagnostics (Clinical, Research)

  • 14.4.3 Precision Medicine and Personalized Therapy

  • 14.4.4 Agriculture and Animal Genomics

  • 14.4.5 Others (Forensics, Infectious Disease Surveillance, Oncology Genomics)

14.5 By Deployment Mode

  • 14.5.1 Cloud‑Based

  • 14.5.2 On‑Premise

14.6 By End User​

  • 14.6.1 Pharmaceutical and Biotechnology Companies

  • 14.6.2 Hospitals and Healthcare Providers

  • 14.6.3 Research Institutes and Academic Centers

  • 14.6.4 Others (Government Agencies, Forensic Labs, Agriculture Organizations)

14.7 By Region

  • 14.7.1 North America

  • 14.7.2 Europe

  • 14.7.3 Asia Pacific

  • 14.7.4 Latin America

  • 14.7.5 Middle East and Africa

15. Regional Market Analysis

15.1 North America

  • 15.1.1 Market Overview and Key Trends

  • 15.1.2 Market Size and Forecast (2025–2033)

  • 15.1.3 Market Share by Segment

  • 15.1.4 Country‑Level Analysis

    • United States

    • Canada

    • Mexico

  • 15.1.5 Market Attractiveness Analysis

15.2 Europe​

  • 15.2.1 Market Overview and Key Trends

  • 15.2.2 Market Size and Forecast (2025–2033)

  • 15.2.3 Market Share by Segment

  • 15.2.4 Country‑Level Analysis

    • Germany

    • United Kingdom

    • France

    • Italy

    • Spain

    • Nordics (Denmark, Norway, Sweden)

    • Rest of Europe

  • 15.2.5 Market Attractiveness Analysis

15.3 Asia Pacific

  • 15.3.1 Market Overview and Key Trends

  • 15.3.2 Market Size and Forecast (2025–2033)

  • 15.3.3 Market Share by Segment

  • 15.3.4 Country‑Level Analysis

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Singapore

    • ASEAN

    • Rest of Asia Pacific

  • 15.3.5 Market Attractiveness Analysis

15.4 Latin America

  • 15.4.1 Market Overview and Key Trends

  • 15.4.2 Market Size and Forecast (2025–2033)

  • 15.4.3 Market Share by Segment

  • 15.4.4 Country‑Level Analysis

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America

  • 15.4.5 Market Attractiveness Analysis

15.5 Middle East and Africa

  • 15.5.1 Market Overview and Key Trends

  • 15.5.2 Market Size and Forecast (2025–2033)

  • 15.5.3 Market Share by Segment

  • 15.5.4 Country‑Level Analysis

    • GCC Countries (UAE, Saudi Arabia, Qatar, Kuwait)

    • South Africa

    • Egypt

    • Rest of MEA

  • 15.5.5 Market Attractiveness Analysis

16. Competitive Landscape

  • 16.1 Market Concentration and Competitive Intensity

  • 16.2 Market Share Analysis of Key Players (2024/2025)​

  • 16.3 Market Ranking and Positioning Analysis

  • 16.4 Competitive Strategies and Benchmarking

  • 16.5 Recent Developments and Strategic Moves

    • 16.5.1 AI‑Genomics Product Launches and Platform Innovations​

    • 16.5.2 Mergers, Acquisitions, and Strategic Buyouts​

    • 16.5.3 Partnerships, Collaborations, and Licensing Agreements

    • 16.5.4 Regulatory Approvals and CE/FDA Clearances

    • 16.5.5 Geographic Expansion and Market Entry

  • 16.6 Competitive Dashboard and Company Evaluation Matrix

17. Company Profiles

The final report includes a complete list of companies

17.1 Illumina, Inc.

  • Company Overview

  • Financial Performance

  • Product Portfolio

  • Strategic Initiatives

  • SWOT Analysis

17.2 NVIDIA Corporation

17.3 IBM Corporation (IBM Watson Health/Genomics)

17.4 Microsoft Corporation (Azure Genomics)

17.5 Google LLC (Google Cloud Life Sciences)

17.6 Deep Genomics Inc.

17.7 Fabric Genomics (formerly Omicia)

17.8 SOPHiA GENETICS SA

17.9 Tempus AI, Inc.

17.10 Foundation Medicine, Inc. (Roche Group)

17.11 Genomenon, Inc.

17.12 BioNano Genomics, Inc.

17.13 Pacific Biosciences of California, Inc. (PacBio)

17.14 Oxford Nanopore Technologies plc

17.15 GeneDx Holdings Corp.

18. Technology and Innovation Trends

  • 18.1 Advances in Machine Learning and Deep Learning for Genomic Variant Calling and Annotation

  • 18.2 Large Language Models (LLMs) and Generative AI in Genomics Research​

  • 18.3 Integration of AI with Single‑Cell Sequencing and Spatial Transcriptomics​

  • 18.4 Federated Learning and Privacy‑Preserving AI for Multi‑Institutional Genomics​

  • 18.5 AI‑Driven Multi‑Omics Integration (Genomics, Proteomics, Metabolomics)

19. Regulatory and Compliance Landscape

  • 19.1 Overview of Global Regulatory Framework for AI‑Based Genomics Tools

  • 19.2 FDA Software as a Medical Device (SaMD) and AI/ML‑Based Software Guidance​

  • 19.3 EMA and EU AI Act Implications for Clinical Genomics Software

  • 19.4 HIPAA, GDPR, and Genomic Data Privacy Regulations​

  • 19.5 NIH, NHGRI, and Government Genomics Program Compliance

  • 19.6 Impact of Regulatory Harmonization on AI Genomics Market Adoption

20. Patent and Intellectual Property Analysis

  • 20.1 Key Patents in AI‑Based Genomic Sequencing, Variant Calling, and Drug Discovery

  • 20.2 Patent Landscape by Technology (ML, Deep Learning, NLP) and Application​

  • 20.3 Regional Patent Filing Trends (U.S., Europe, Asia Pacific)

  • 20.4 Leading Companies in Patent Holdings​

  • 20.5 Emerging IP Opportunities and White Spaces

21. ESG and Sustainability Analysis

  • 21.1 Environmental Impact of HPC and AI Computing Infrastructure

  • 21.2 Social Responsibility: Equitable Access to Genomics and Precision Medicine​

  • 21.3 Governance, Ethical AI, and Genomic Data Consent Frameworks

  • 21.4 Corporate ESG Initiatives by Leading AI Genomics Players

22. Use Case and Application Analysis

  • 22.1 Pharmaceutical and Biotech R&D: AI‑Driven Drug Target Identification and Lead Optimization

  • 22.2 Clinical Diagnostics: AI‑Powered Variant Interpretation and Rare Disease Diagnosis

  • 22.3 Precision Oncology: Tumor Genomics, Companion Diagnostics, and Treatment Stratification​

  • 22.4 Population Genomics: National Biobanks, GWAS, and Epidemiological Studies​

  • 22.5 Agriculture and Animal Genomics: Precision Breeding and Crop Improvement​

23. Commercial Use Cases Across Industries

  • 23.1 Pharmaceutical Companies: AI‑Driven Pipeline Prioritization and Clinical Trials

  • 23.2 Biotech Startups: AI‑Native Genomics Platform Development

  • 23.3 Clinical Laboratories and Diagnostic Centers: AI‑Enhanced Reporting and Interpretation​

  • 23.4 Cloud and IT Companies: AI Infrastructure and Genomics‑as‑a‑Service​

  • 23.5 Research Institutes and Academic Centers: Multi‑Omics and Population Health Research

24. Consumer and End‑User Analysis

  • 24.1 Purchase Decision Factors (Platform Accuracy, Scalability, Regulatory Compliance, Cost)

  • 24.2 Total Cost of Ownership of AI Genomics Solutions

  • 24.3 Technology Adoption Maturity Across Pharma, Biotech, and Healthcare Segments​

  • 24.4 End‑User Pain Points and Unmet Needs

  • 24.5 Impact of Data Privacy Concerns on Platform Selection and Cloud Adoption​

25. AI in Genomics Market Trends and Strategies

  • 25.1 Current Market Trends

    • 25.1.1 Dominance of Drug Discovery as the Largest Application Segment

    • 25.1.2 Software Segment Leading Component Revenue​

    • 25.1.3 Cloud‑Based Deployment Accelerating AI Genomics Adoption

  • 25.2 Market Entry and Expansion Strategies

  • 25.3 Product Innovation and Platform Differentiation Strategies

  • 25.4 Pricing, Licensing, and Subscription Model Strategies

  • 25.5 Partnership, Collaboration, and Co‑Development Strategies

26. Strategic Recommendations

  • 26.1 Recommendations for Established Genomics and AI Platform Leaders​

  • 26.2 Recommendations for Emerging Startups and Niche AI Genomics Companies

  • 26.3 Recommendations for Pharma, Biotech, and Healthcare Investors

  • 26.4 Regional Expansion and Emerging Market Penetration Strategies​

  • 26.5 R&D and Technology Investment Priorities (LLMs, Federated Learning, Multi‑Omics)​

  • 26.6 Regulatory Strategy and Compliance Roadmap for AI Genomics Software​

27. Key Mergers and Acquisitions

  • 27.1 Overview of M&A Activity in AI in Genomics Market​

  • 27.2 Major Transactions and Strategic Rationale

  • 27.3 Impact on Market Dynamics and Competitive Positioning

28. High‑Potential Segments and Growth Strategies

  • 28.1 High‑Growth Segments (Drug Discovery, Precision Medicine, Single‑Cell Genomics)

  • 28.2 Emerging Geographies Offering Strong Opportunities

  • 28.3 Growth Strategies

    • 28.3.1 Market Trend‑Based Strategies

    • 28.3.2 Competitor Benchmarking and Differentiation Strategies

29. Future Market Outlook and Trends (2026–2033)

  • 29.1 Evolution Toward LLM‑ and Generative AI‑Powered Genomics Platforms​

  • 29.2 Integration with Multi‑Omics, Spatial Transcriptomics, and Wearable Biosensors​

  • 29.3 Expansion of Population‑Scale Genomics and National Precision Medicine Programs

  • 29.4 AI Genomics Market Outlook in Emerging Healthcare and Life Sciences Markets​

30. Conclusion

  • 30.1 Summary of Key Findings

  • 30.2 Market Outlook (2025–2033)

  • 30.3 Future Growth Drivers and Opportunities

  • 30.4 Final Insights and Strategic Perspectives

31. Appendix

  • 31.1 List of Abbreviations and Acronyms

  • 31.2 Glossary of Technical Terms (NGS, WGS, GWAS, LLM, SaMD, etc.)

  • 31.3 Research Instruments and Questionnaires (Sample)

  • 31.4 List of Figures and Tables

  • 31.5 List of Primary and Secondary Data Sources

  • 31.6 Additional Resources and References

32. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.